A screenshot of Hims & Hers’ Super Bowl commercial (Sherwood News)

Hims slips after US lawmakers introduce bill cracking down on compounding

Analysts at Citi said that the bill presents a headwind for Hims.

12/10/25 12:16PM

Hims & Hers slipped on Wednesday after members of Congress introduced a bill that would limit its ability to sell copies of blockbuster weight-loss drugs made by Eli Lilly and Novo Nordisk.

The bill, “Safeguarding Americans from Fraudulent and Experimental (SAFE) Drugs Act of 2025,” is sponsored by Rep. Rudy Yakym III and Rep. Andre Carson, both of Indiana, where Lilly is headquartered. The bill would raise the bar for when it is legal to dispense compounded versions of popular weight-loss drugs, an industry that has exploded in the past couple of years.

Analysts at Citi said that the bill presents a headwind for Hims. It would “significantly curtail [Hims’] ability to compound GLP-1s,” the product category where the company has seen the most revenue growth in the past year, the analysts said in a Wednesday morning note.

Under federal law, compounding pharmacies can sell exact copies of a branded medication only when it is in a shortage. Lilly and Novo’s GLP-1s were taken off the Food and Drug Administration’s shortage list earlier this year, meaning compounding pharmacies could only continue selling bespoke versions for individual patients.

Telehealth companies like Hims have continued to market compounded GLP-1s, often referring to them “personalized.” The bill would raise the bar for when that is allowed, requiring a doctor to determine whether a compounded version creates a “significant difference” over the commercially available version sold by drugmakers.

The drugmakers have pushed back on telehealth companies’ claim of “personalization,” arguing that the drugs are mass produced and not made for specific patients like the law intends. Lilly and Novo have taken some of these companies to court, and have for the most part lost. The drugmakers have also urged the FDA to up enforcement, but it shares regulatory responsibility with a patchwork of state regulators.

The SAFE Act may empower the FDA to crack down on compounders, which have been nibbling away at drugmakers’ market share.

Hims did not immediately respond to a request for comment.

Max Knoblauch18m

Budget airline stocks dip as Spirit pilots ratify contract that’ll help the carrier stay afloat

Low-cost airlines JetBlue and Frontier are trading lower on Thursday following the news that Spirit Airlines pilots ratified modifications to their labor contract that will lower costs for the carrier, which filed for bankruptcy in August.

According to the Air Line Pilots Association (ALPA), Spirit pilots approved a deal that included “temporary reductions to pay rates and retirement contributions.” Beginning January 1, hourly pay will be reduced 8% and retirement contributions will drop by half from 16% to 8%.

"Spirit pilots made a difficult choice that provides the Company with what it needs from labor to secure financing and complete its restructuring,” said Captain Ryan P. Muller, chairman of the Spirit Airlines Master Executive Council.

Wall Street sees Jetblue and Frontier as the biggest beneficiaries to Spirit’s woes, and both carriers have attempted to purchase Spirit in recent years.

Matt Phillips41m

Planet Labs rips on strong earnings report

Satellite services company Planet Labs was on track for a new record closing high after rising more than 35% in early afternoon trading on Thursday.

The roughly $5 billion company posted better-than-expected quarterly results and guided toward higher-than-expected sales for the current quarter after the close of trading Wednesday.

“AI continues to be a major tailwind as the company is seeing significant demand through enhanced capabilities for its advanced satellite data solutions,” wrote Wedbush tech analyst Dan Ives, adding “We continue to believe the PL is well-positioned at the intersection of Space and AI.” He has an “outperform” — basically a “buy” — rating and a price target of $20 on the stock.

Other satellite services AST SpaceMobile and Rocket Lab also enjoyed a bump on Thursday, seemingly riding the momentum of Planet Labs’ numbers.

Planet Labs Stock Soars After Earnings Report. Why Shares Are Headed to the Moon.

Other satellite services AST SpaceMobile and Rocket Lab also enjoyed a bump on Thursday, seemingly riding the momentum of Planet Labs’ numbers.

The East Side of the US Capitol Building in the early morning, Washington DC, USA.

Health insurers rise after the Senate rejects competing healthcare plans

The Democratic plan would have extended tax credits, while the GOP plan would have replaced them with HSAs.

J. Edward Moreno44m

Max Knoblauch3h

Rivian sure picked a bad time for its AI Day as investors dump tech stocks

The event coordination team at Rivian is probably having a bad one, as investors dumped the stock ahead of its “Autonomy and AI Day” amid a broader AI trade sell-off.

Heading into the event that began at noon ET, Rivian shares were down 5%, following a strongly negative reaction to Oracle’s earnings results. The stock began climbing as Rivian’s event started, but remains in the red on the day.

A year flush with tariffs and the end of the EV tax credit has pushed Rivian to pitch a techier version of its future. During Thursday’s event, Rivian said its forthcoming vehicles would ditch Nvidia chips for its own AI chips produced by Taiwan Semiconductor.

The vehicles will feature lidar sensors, enabling “level 4” autonomous driving (similar to Google’s Waymo), the company said. According to CEO RJ Scaringe, the updates will allow Rivian to “pursue opportunities in the rideshare space,” hinting at future robotaxi plans, which rivals Tesla and Lucid have already begun.

Wall Street appears skeptical of Rivian, with Morgan Stanley this week downgrading the stock to “underweight” and dropping its price target to $12. Lucid, which in October announced it’s planning a privately owned autonomous car built with Nvidia tech, also received a downgrade.

Rivian turns to AI, autonomy to woo investors as EV sales stall

Luke Kawa3h

Robinhood tumbles after November trading volumes post monthly drop across equities, options, and crypto

Robinhood Markets is getting crushed today, and not just because it’s the place where people go to buy AI stocks (which are under big pressure after Oracle’s earnings report). As stocks retreated in November, activity on the platform did, too.

(Robinhood Markets Inc. is the parent company of Sherwood Media, an independently operated media company subject to certain legal and regulatory restrictions.)

The brokerage reported that November trading volumes fell across equities, options, and crypto compared to October. Equity notional volumes were down 37% month on month, options contracts traded were off 28%, and crypto notional volumes fell double digits. The bright spot: its prediction markets business is still in boom mode, with 3 billion contracts traded, up 20% versus the prior month.

Cantor Fitzgerald analyst Brett Knoblauch trimmed his price target on the shares to $152 from $155 following this release, noting that this monthly decline was somewhat expected.